Quality Assessment of Cryopreserved Human Biological Samples from the Biobank of Barretos Cancer Hospital

Neuber, Ana Caroline; Komoto, Tatiana Takahasi; Silva, Eduardo Caetano Albino da; Duval, Vinicius; Scapulatempo‐Neto, Cristovam; Marques, Márcia Maria Chiquitelli

doi:10.1089/bio.2021.0131

Cited by 2 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All the samples are from primary tumor before any systemic treatment exposure and were reviewed by an independent pathologist. Biological samples of fresh frozen tumoral tissue were retrieved at the Biobank of the Barretos Cancer Hospital (BB-BCH), ensuring the quality of processes and the suitability of the biospecimens for research ( 33 ).…”

Section: Methodsmentioning

confidence: 99%

“…Clinicopathologic data were retrieved from the electronic medical records, including data on age, date of initial diagnosis, histological type, pathologic diagnosis, overall survival, and treatment history with chemotherapy. All information that could identify the patients was collected and managed using REDCap electronic data capture tools hosted at Barretos Cancer Hospital (31,32), to ensure the confidentiality of the data and the anonymity of the patients. REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed to support data capture for research studies, providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for data integration and interoperability with external sources.…”

Section: Study Population Materialsmentioning

confidence: 99%

See 1 more Smart Citation

Somatic mutation detection and KRAS amplification in testicular germ cell tumors

Cabral

Pacanhella²,

Lengert³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundTesticular Germ Cell Tumors (TGCT) are the most common cancer among young adult men. The TGCT histopathology is diverse, and the frequency of genomic alterations, along with their prognostic role, remains largely unexplored. Herein, we evaluate the mutation profile of a 15-driver gene panel and copy number variation of KRAS in a large series of TGCT from a single reference cancer center.Materials and methodsA cohort of 97 patients with TGCT, diagnosed at the Barretos Cancer Hospital, was evaluated. Real-time PCR was used to assess copy number variation (CNV) of the KRAS gene in 51 cases, and the mutation analysis was performed using the TruSight Tumor 15 (Illumina) panel (TST15) in 65 patients. Univariate analysis was used to compare sample categories in relation to mutational frequencies. Survival analysis was conducted by the Kaplan–Meier method and log-rank test.ResultsKRAS copy number gain was a very frequent event (80.4%) in TGCT and presented a worse prognosis compared with the group with no KRAS copy gain (10y-OS, 90% vs. 81.5%, p = 0.048). Among the 65 TGCT cases, different variants were identified in 11 of 15 genes of the panel, and the TP53 gene was the most recurrently mutated driver gene (27.7%). Variants were also detected in genes such as KIT, KRAS, PDGFRA, EGFR, BRAF, RET, NRAS, PIK3CA, MET, and ERBB2, with some of them potentially targetable.ConclusionAlthough larger studies incorporating collaborative networks may shed the light on the molecular landscape of TGCT, our findings unveal the potential of actionable variants in clinical management for applying targeted therapies.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Study Population Materialsmentioning

confidence: 99%